Medical Oncology

Residual disease   

Questions discussed in this category


http://www.nejm.org/doi/full/10.1056/NEJMoa1612645?rss=searchAndBrowse&#article_abstract If so, how do you sequence it with adjuvant radiotherapy...

Are you using post-neoadjuvant Xeloda based on preliminary data from the CREATE-X trial? Does BRCA mutation influence your decision?


Papers discussed in this category


N. Engl. J. Med.,

ESMO Open, 2016-01-01